Upload Avatar (500 x 500)
Bai Shan Jiang
Medical School
Wuhan University
Hubei
Language: Chinese, English
Small Molecules
Inhibitors
Protein Degradation
Protac
Molecular Glue
Drug Resistance
Target Proteins
Disease-Related Proteins
Biological Function
Clinical Potential
Areas of Focus
- Small molecule inhibitors
- Protein degraders
Work Experience
- 2011.7-2015.8 Assistant Researcher, Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
- 2015.9-2019.3 Postdoc, Dana-Farber Cancer Institute, Harvard Medical School
- 2019.4-2022.1 Research Scientist, Dana-Farber Cancer Institute, Harvard Medical School
- 2022.2-present Professor, Doctoral Supervisor, School of Pharmaceutical Sciences, Wuhan University
Academic Background & Achievements
- 2001-2005 Bachelor: Xiangtan University
- 2005-2011 PhD: Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences
Publications
- INK4 tumor suppressor proteins mediate resistance to CDK4/6 kinase inhibitors, Li, Q.; Jiang, B.; Guo, J.; Shao, H.; Del Priore, I. S.; Chang, Q.; Kudo, R.; Li, Z.; Razavi, P.; Liu, B.; Boghossian, A. S.; Rees, M. G.; Ronan, M. M.; Roth, J. A.; Donovan, K. A.; Palafox, M.; Reis-Filho, J. S.; de Stanchina, E.; Fischer, E. S.; Rosen, N.; Serra, V.; Koff, A.; Chodera, J. D.; Gray, N. S.; Chandarlapaty, S., 2021
- Structure-Activity Relationship Study of THZ531 Derivatives Enables the Discovery of BSJ-01-175 as a Dual CDK12/13 Covalent Inhibitor with Efficacy in Ewing Sarcoma, Jiang, B.; Jiang, J.; Kaltheuner, I. H.; Iniguez, A. B.; Anand, K.; Ferguson, F. M.; Ficarro, S. B.; Alex Seong, B. K.; Greifenberg, A. K.; Dust, S.; Kwiatkowski, N. P.; Marto, J. A.; Stegmaier, K.; Zhang, T.; Geyer, M.; Gray, N. S., 2021
- Discovery and resistance mechanism of a selective CDK12 degrader, Jiang, B.; Yang, G.; Che, J.; Lu, W.; Kaltheuner, I. H.; Dries, R.; Kalocsay, M.; Berberich, M. J.; Jiang, J.; You, I.; Kwiatkowski, N.; Riching, K. M.; Daniels, D. L.; Sorger, P. K.; Geyer, M.; Zhang, T.; Gray, N. S., 2021
- Characterization of a dual covalent inhibitor targeting MKK4 and MKK7, Jiang, J.; Jiang, B.; Jarrod, S.; Zhang, T.H.; Gray, N.S., 2020
- Development of dual and selective degraders of cyclin-dependent kinases 4 and 6, Jiang, B.; Wang, E. S.; Donovan, K. A.; Liang, Y.; Fischer, E. S.; Zhang, T.; Gray, N. S., 2019
- Homolog-selective degradation as a strategy to probe the function of CDK6 in AML, Brand, M.; Jiang, B.; Bauer, S.; Donovan, K. A.; Wang, E. S.; Nowak, R. P.; Yuan, J. C.; Zhang, T.; Kwiatkowski, N.; Müller, A. C.; Fischer, E. S.; Gray, N. S.; Winter, G. E., 2019
- A Chemoproteomic Strategy for Direct and Proteome-wide Covalent Inhibitor Target-site Identification, Browne, C. M.; Jiang, B.; Ficarro, S. B.; Doctor, Z. M.; Johnson, J. L.; Card, J. D.; Sivakumaren, S. C.; Alexander, W. M.; Yaron, T.; Murphy, C. J.; Kwiatkowski, N. P.; Zhang, T.; Cantley, L. C.; Gray, N. S.; Marto, J. A., 2019
- Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation, Olson, C. M.; Jiang, B.; Erb, M. A.; Liang, Y.; Doctor, Z. M.; Zhang, Z.; Zhang, T.; Kwiatkowski, N.; Boukhali, M.; Green, J. L.; Haas, W.; Fischer, E. S.; Young, R. A.; Bradner, J. E.; Winter, G. E.; Gray, N. S., 2018
